NCT00285623

Brief Summary

The purpose of this study is to collect information, after exposure to TachoSil ®, of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding. In addition, pharmacoeconomic data will be collected.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2005

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2005

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

December 21, 2005

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 2, 2006

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2008

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2008

Completed
Last Updated

May 7, 2012

Status Verified

July 1, 2009

Enrollment Period

2.3 years

First QC Date

December 21, 2005

Last Update Submit

May 4, 2012

Conditions

Keywords

Collection of all thromboembolic events,immunological events and drug interactions leading to thromboembolic events or majorbleeding after exposure to TachoSil®.

Interventions

treatment in surgery for improvement of haemostasis where standard techniques are insufficient

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients exposed to TachoSil® of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding.

You may qualify if:

  • All subjects, treated with TachoSil ® by the participating physicians, will be registered with a set of basic data from their already existing data (i.e. no additional diagnostic procedures will be performed).
  • Subjects who will provide their written informed consent to use existing data, allow direct access to data and data processing.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nycomed

Roskilde, 4000, Denmark

Location

Related Publications (1)

  • Birth M, Figueras J, Bernardini S, Troen T, Gunther K, Mirza D, Mortensen FV. Collagen fleece-bound fibrin sealant is not associated with an increased risk of thromboembolic events or major bleeding after its use for haemostasis in surgery: a prospective multicentre surveillance study. Patient Saf Surg. 2009 Jun 22;3(1):13. doi: 10.1186/1754-9493-3-13.

MeSH Terms

Conditions

Blood Loss, Surgical

Interventions

FibrinogenThrombinTachoSil

Condition Hierarchy (Ancestors)

HemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsIntraoperative Complications

Intervention Hierarchy (Ancestors)

Acute-Phase ProteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsBlood Coagulation FactorsProtein PrecursorsBiological FactorsSerine EndopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesSerine Proteases

Study Officials

  • Nycomed Clinical Trial Operations

    Headquarters

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 21, 2005

First Posted

February 2, 2006

Study Start

December 1, 2005

Primary Completion

April 1, 2008

Study Completion

July 1, 2008

Last Updated

May 7, 2012

Record last verified: 2009-07

Locations